TN2013000237A1 - Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor - Google Patents

Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor

Info

Publication number: TN2013000237A1
Authority: TN; Tunisia
Prior art keywords: quinolin; imidazo; compound; kinase; dual inhibitor
Prior art date: 2011-01-14

Application number

TNP2013000237A

Other languages

English (en)

Inventor

David Anthony Barda

Mary Margaret Mader

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-14

Filing date

2013-06-03

Publication date

2014-11-10

2013-06-03 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-11-10 Publication of TN2013000237A1 publication Critical patent/TN2013000237A1/fr

Links

-1 Imidazo [4, 5 -c] quinolin- 2 -one compound Chemical class 0.000 title abstract 2
101150097381 Mtor gene Proteins 0.000 title 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
229940125436 dual inhibitor Drugs 0.000 title 1
102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091007960 PI3Ks Proteins 0.000 abstract 1
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2013000237A 2011-01-14 2013-06-03 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor TN2013000237A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161432958P	2011-01-14	2011-01-14
PCT/US2012/020897 WO2012097039A1 (fr)	2011-01-14	2012-01-11	Composé d'imidazo[4,5-c]quinolin-2-one et son utilisation comme inhibiteur double de kinase pi3/mtor

Publications (1)

Publication Number	Publication Date
TN2013000237A1 true TN2013000237A1 (en)	2014-11-10

Family

ID=45531593

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000237A TN2013000237A1 (en)	2011-01-14	2013-06-03	Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor

Country Status (40)

Country	Link
US (2)	US8440829B2 (fr)
EP (1)	EP2663564B1 (fr)
JP (1)	JP5891247B2 (fr)
KR (1)	KR101561360B1 (fr)
CN (1)	CN103282364B (fr)
AR (1)	AR084551A1 (fr)
AU (1)	AU2012205619B2 (fr)
BR (1)	BR112013017672A2 (fr)
CA (1)	CA2824760C (fr)
CL (1)	CL2013002005A1 (fr)
CO (1)	CO6731133A2 (fr)
CR (1)	CR20130289A (fr)
CY (1)	CY1116007T1 (fr)
DK (1)	DK2663564T3 (fr)
DO (1)	DOP2013000158A (fr)
EA (1)	EA022163B1 (fr)
EC (1)	ECSP13012764A (fr)
ES (1)	ES2531891T3 (fr)
GT (1)	GT201300180A (fr)
HK (1)	HK1188454A1 (fr)
HR (1)	HRP20150135T1 (fr)
HU (1)	HUE024426T2 (fr)
IL (1)	IL227165A (fr)
JO (1)	JO3003B1 (fr)
ME (1)	ME02019B (fr)
MX (1)	MX2013008185A (fr)
MY (1)	MY164705A (fr)
PE (1)	PE20140864A1 (fr)
PH (1)	PH12013501493A1 (fr)
PL (1)	PL2663564T3 (fr)
PT (1)	PT2663564E (fr)
RS (1)	RS53828B1 (fr)
SG (1)	SG191744A1 (fr)
SI (1)	SI2663564T1 (fr)
SV (1)	SV2013004496A (fr)
TN (1)	TN2013000237A1 (fr)
TW (1)	TWI518086B (fr)
UA (1)	UA109921C2 (fr)
WO (1)	WO2012097039A1 (fr)
ZA (1)	ZA201304757B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3003B1 (ar)	2011-01-14	2016-09-05	Lilly Co Eli	مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en)	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
US20160264570A1 (en) *	2013-11-15	2016-09-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv	Method of blocking transmission of malarial parasite
TWI609687B (zh)	2015-04-14	2018-01-01	美國禮來大藥廠	平滑肌肉瘤之標靶性治療
TW201703769A (zh)	2015-05-08	2017-02-01	美國禮來大藥廠	用於癌症的組合療法
GB201516504D0 (en) *	2015-09-17	2015-11-04	Astrazeneca Ab	Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
BR112018011203A2 (pt) *	2015-12-15	2018-11-21	Lilly Co Eli	terapia de combinação para câncer
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
AU2017249988C1 (en) *	2016-04-12	2023-02-16	Eli Lilly And Company	Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer
RU2747788C2 (ru) *	2016-04-12	2021-05-14	Эли Лилли Энд Компани	Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
US10688104B2 (en)	2016-05-20	2020-06-23	Eli Lilly And Company	Combination therapy with Notch and PD-1 or PD-L1 inhibitors
WO2018017410A1 (fr)	2016-07-22	2018-01-25	Eli Lilly And Company	Polythérapie à base d'abemaciclib et d'un inhibiteur double de kinase pi3 /mtor, destinée à être utilisée dans le traitement du cancer du sein
WO2018063873A1 (fr) *	2016-09-27	2018-04-05	Eli Lilly And Company	Polythérapie à base d'abémaciclib et d'un inhibiteur double de kinase pi3/mtor destinée à être utilisée dans le traitement du cancer du pancréas
EP3525796A1 (fr)	2016-10-12	2019-08-21	Eli Lilly and Company	Traitement ciblé de lymphome à cellules t matures
JP2020507605A (ja)	2017-02-17	2020-03-12	フレッドハッチンソンキャンサーリサーチセンター	Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
KR20200099137A (ko)	2017-11-06	2020-08-21	주노 쎄러퓨티크스 인코퍼레이티드	세포 요법 및 감마 세크레타제 억제제의 조합
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
CN110386932A (zh)	2018-04-20	2019-10-29	艾科思莱德制药公司	用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
FI3813946T3 (fi)	2018-06-15	2024-06-25	Janssen Pharmaceutica Nv	Rapamysiinianalogeja ja niiden käyttötapoja
WO2020081329A1 (fr) *	2018-10-18	2020-04-23	Camp4 Therapeutics Corporation	Méthodes et compositions pour moduler l'expression de pcsk9 et d'angptl3
TW202134234A (zh)	2019-12-05	2021-09-16	美商奈維特製藥公司	雷帕黴素類似物及其用途
WO2022060377A1 (fr) *	2020-09-21	2022-03-24	Wei Zhong	Composés substitués de 1-(3,3-difluoropipéridin-4-yl)-imidazo[4,5-c]quinoléin-2-one présentant une aptitude à traverser la barrière hémato-encéphalique
EP3992191A1 (fr)	2020-11-03	2022-05-04	Deutsches Krebsforschungszentrum	Dérivés d'imidazo[4,5-c]quinoline et leur utilisation en tant qu'inhibiteurs de kinase atm

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
BRPI0416801A (pt)	2003-11-21	2007-01-09	Novartis Ag	derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AR046845A1 (es) *	2003-11-21	2005-12-28	Novartis Ag	Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
US8158794B2 (en) *	2005-02-23	2012-04-17	3M Innovative Properties Company	Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
ES2429170T3 (es)	2005-11-04	2013-11-13	3M Innovative Properties Company	1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
US8329721B2 (en)	2006-03-15	2012-12-11	3M Innovative Properties Company	Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
JP5591809B2 (ja)	2008-09-30	2014-09-17	ファイザー・インク	イミダゾ［１，５］ナフチリジン化合物、その医薬への使用、および組成物
EP2438063A1 (fr) *	2009-06-04	2012-04-11	Novartis AG	Composes de 1h-imidazo[4,5-c]quinolinone, utiles pour le traitement de maladies proliferatives
BRPI1010621A2 (pt)	2009-06-04	2016-06-21	Novartis Ag	derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
CA2766967A1 (fr) *	2009-06-30	2011-01-06	Piramal Life Sciences Limited	Derives d'imidazo[4,5-c]quinoleine et leur utilisation dans le traitement de tumeurs et/ou d'une inflammation
BR112013013837A2 (pt) *	2010-12-06	2016-09-13	Piramal Entpr Ltd	derivados de substituição de imidazoquinolina
JO3003B1 (ar)	2011-01-14	2016-09-05	Lilly Co Eli	مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

2011
- 2011-12-20 JO JOP/2011/0389A patent/JO3003B1/ar active
- 2011-12-22 AR ARP110104894A patent/AR084551A1/es unknown
- 2011-12-23 TW TW100148428A patent/TWI518086B/zh not_active IP Right Cessation
2012
- 2012-01-11 KR KR1020137018235A patent/KR101561360B1/ko not_active Expired - Fee Related
- 2012-01-11 MX MX2013008185A patent/MX2013008185A/es active IP Right Grant
- 2012-01-11 DK DK12701207.8T patent/DK2663564T3/en active
- 2012-01-11 RS RS20150095A patent/RS53828B1/en unknown
- 2012-01-11 EP EP12701207.8A patent/EP2663564B1/fr active Active
- 2012-01-11 AU AU2012205619A patent/AU2012205619B2/en not_active Ceased
- 2012-01-11 CA CA2824760A patent/CA2824760C/fr not_active Expired - Fee Related
- 2012-01-11 ME MEP-2015-14A patent/ME02019B/me unknown
- 2012-01-11 JP JP2013549509A patent/JP5891247B2/ja not_active Expired - Fee Related
- 2012-01-11 US US13/347,886 patent/US8440829B2/en not_active Expired - Fee Related
- 2012-01-11 MY MYPI2013701219A patent/MY164705A/en unknown
- 2012-01-11 BR BR112013017672A patent/BR112013017672A2/pt not_active Application Discontinuation
- 2012-01-11 SI SI201230117T patent/SI2663564T1/sl unknown
- 2012-01-11 CN CN201280005256.0A patent/CN103282364B/zh not_active Expired - Fee Related
- 2012-01-11 PT PT127012078T patent/PT2663564E/pt unknown
- 2012-01-11 PE PE2013001553A patent/PE20140864A1/es active IP Right Grant
- 2012-01-11 WO PCT/US2012/020897 patent/WO2012097039A1/fr active Application Filing
- 2012-01-11 ES ES12701207.8T patent/ES2531891T3/es active Active
- 2012-01-11 PH PH1/2013/501493A patent/PH12013501493A1/en unknown
- 2012-01-11 HU HUE12701207A patent/HUE024426T2/en unknown
- 2012-01-11 PL PL12701207T patent/PL2663564T3/pl unknown
- 2012-01-11 SG SG2013047311A patent/SG191744A1/en unknown
- 2012-01-11 EA EA201390823A patent/EA022163B1/ru not_active IP Right Cessation
- 2012-11-01 UA UAA201308519A patent/UA109921C2/ru unknown
2013
- 2013-04-16 US US13/863,411 patent/US8658668B2/en not_active Expired - Fee Related
- 2013-06-03 TN TNP2013000237A patent/TN2013000237A1/fr unknown
- 2013-06-14 CR CR20130289A patent/CR20130289A/es unknown
- 2013-06-24 IL IL227165A patent/IL227165A/en active IP Right Grant
- 2013-06-25 ZA ZA2013/04757A patent/ZA201304757B/en unknown
- 2013-07-01 DO DO2013000158A patent/DOP2013000158A/es unknown
- 2013-07-09 CL CL2013002005A patent/CL2013002005A1/es unknown
- 2013-07-11 GT GT201300180A patent/GT201300180A/es unknown
- 2013-07-12 EC ECSP13012764 patent/ECSP13012764A/es unknown
- 2013-07-12 SV SV2013004496A patent/SV2013004496A/es unknown
- 2013-07-25 CO CO13176485A patent/CO6731133A2/es unknown
2014
- 2014-02-19 HK HK14101571.9A patent/HK1188454A1/xx not_active IP Right Cessation
2015
- 2015-01-30 CY CY20151100096T patent/CY1116007T1/el unknown
- 2015-02-04 HR HRP20150135AT patent/HRP20150135T1/hr unknown

Also Published As

Publication number	Publication date
EP2663564B1 (fr)	2014-12-17
ZA201304757B (en)	2014-12-23
ES2531891T3 (es)	2015-03-20
PH12013501493A1 (en)	2021-06-02
MX2013008185A (es)	2013-08-21
CA2824760A1 (fr)	2012-07-19
WO2012097039A1 (fr)	2012-07-19
US20130237562A1 (en)	2013-09-12
UA109921C2 (uk)	2015-10-26
NZ611541A (en)	2015-02-27
EP2663564A1 (fr)	2013-11-20
SI2663564T1 (sl)	2015-01-30
JO3003B1 (ar)	2016-09-05
MY164705A (en)	2018-01-30
PE20140864A1 (es)	2014-07-19
CR20130289A (es)	2013-10-07
ME02019B (me)	2015-05-20
EA022163B1 (ru)	2015-11-30
PL2663564T3 (pl)	2015-05-29
JP5891247B2 (ja)	2016-03-22
DOP2013000158A (es)	2013-11-30
HRP20150135T1 (en)	2015-03-13
US8658668B2 (en)	2014-02-25
KR101561360B1 (ko)	2015-10-16
US20120184577A1 (en)	2012-07-19
CL2013002005A1 (es)	2013-12-27
TWI518086B (zh)	2016-01-21
ECSP13012764A (es)	2013-09-30
JP2014502638A (ja)	2014-02-03
GT201300180A (es)	2014-04-08
KR20130116302A (ko)	2013-10-23
AU2012205619B2 (en)	2015-05-21
AR084551A1 (es)	2013-05-22
IL227165A (en)	2016-06-30
HK1188454A1 (en)	2014-05-02
CN103282364B (zh)	2015-06-17
US8440829B2 (en)	2013-05-14
SG191744A1 (en)	2013-08-30
CA2824760C (fr)	2016-03-15
AU2012205619A1 (en)	2013-06-27
CN103282364A (zh)	2013-09-04
BR112013017672A2 (pt)	2018-09-18
EA201390823A1 (ru)	2013-12-30
DK2663564T3 (en)	2015-01-12
SV2013004496A (es)	2017-11-07
RS53828B1 (en)	2015-06-30
CY1116007T1 (el)	2017-01-25
PT2663564E (pt)	2015-02-24
HUE024426T2 (en)	2016-01-28
CO6731133A2 (es)	2013-08-15
TW201307343A (zh)	2013-02-16

Publication	Publication Date	Title
TN2013000237A1 (en)	2014-11-10	Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
PH12019501321B1 (en)	2020-10-12	Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
HK1139863A1 (en)	2010-09-30	Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
SA515360469B1 (ar)	2017-07-11	مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2020002150A (es)	2021-07-07	Terapia de combinación para el tratamiento del cáncer.
PH12013500064A1 (en)	2013-03-11	Combinations of kinase inhibitors for the treatment of cancer
MX2013005826A (es)	2013-08-27	Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
EA201490194A1 (ru)	2014-04-30	Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
MX2013011332A (es)	2014-04-16	Combinaciones de compuestos inhibidores de akt y vemurafenib y metodos de uso de los mismos.
MX360634B (es)	2018-11-12	Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
UA117830C2 (uk)	2018-10-10	Похідні біпіразолу як інгібітори jak
WO2012068106A3 (fr)	2012-08-16	Benxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs procédés d'utilisation et de fabrication
WO2012068096A3 (fr)	2012-11-08	Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs méthodes d'utilisation et de fabrication
HK1140141A1 (en)	2010-10-08	Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2015016421A (es)	2016-03-03	Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX359207B (es)	2018-09-19	Compuesto de pirrolo [2,1-f] [1,2,4]triazina, y método de preparación y aplicación del mismo.
MX2015016425A (es)	2016-03-03	Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
JO3145B1 (ar)	2017-09-20	مركبات مفيدة لتثبيط chk1
WO2014160177A3 (fr)	2015-05-14	Inhibiteurs quinazolines de pi3k
TH149217B (th)	2016-04-26	สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้ง คู่สำหรับ Pl3 คิเนส/MTOR